ACC 24 Late-Breaker Discussion: The EMPACT-MI Trial

Published: 06 Apr 2024

  • Views:

    Views Icon 386
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

ACC.24 — Join Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA), and Principal Investigator, Dr Javed Butler (University of Mississippi Medical Center, US), as they discuss the key findings from the EMPACT-MI trial (Boehringer Ingelheim)(NCT04509674).

In this multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial, investigators evaluated the effect of empagliflozin, an SGLT2 inhibitor, on hospitalisation for heart failure (HF) and mortality in patients with acute myocardial infarction (MI).
The trial recruited 6522 participants, including eligible patients who presented with spontaneous MI alongside new signs or symptoms of pulmonary congestion requiring treatment, new left ventricular dysfunction (LVEF < 45%), and at least one additional risk factor for the development of future HF. The primary outcome measure was the composite of time to first heart failure hospitalisation or all-cause mortality up to 26 months.

Findings, presented at ACC.24 showed that empagliflozin did not significantly reduce the risk of time to first HHF or all-cause death following AMI. Furthermore, empagliflozin demonstrated 23% and 33% relative risk reduction of first HHF and total HHF, components of the primary and first key secondary endpoints respectively.

For more content from ACC.24 head to the Late-breaking Science Video Collection.

Recorded remotely from Jackson and Hamilton, 2024.

Support: This is an independent content produced by Radcliffe Cardiology.

Editor: Mirjam Boros
Videographer: Mike Knight


You must be to comment. If you are not registered, you can register here.